UNSPSC 51161719: Prethcamide

This classification denotes a cns stimulant with the molecular formula C13H24N2O2.C12H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41A1FCW148, chemically known as 2-butenamide, n-(1-((dimethylamino)carbonyl)propyl)-n-ethyl-, mixt. with n-(1-((dimethylamino)carbonyl)propyl)-n-propyl-2-butenamide but generally known as prethcamide, which bears US NIH Compound Identifier 71672. European Medicines Agency schedules Prethcamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35623.

UNSPSC 51161719 Prethcamide is a Commodity code, but the recent state and local opportunities tagged under it do not reflect actual procurement of prethcamide—a pharmaceutical stimulant—by any jurisdiction. Instead, the code captures a heterogeneous mix of pharmacy-related solicitations spanning naloxone distribution, on-site pharmacy services, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals through cooperative purchasing. The issuing bodies include county health departments (Seminole County, Florida), county government employer health plans (Hall County, Georgia), state health agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). The scope reflects acquisitions of finished pharmaceutical products, pharmacy services, and drug-distribution logistics rather than procurement of a single active pharmaceutical ingredient.

Activity is concentrated in Florida, Georgia, Texas, and Minnesota, with MMCAP's multi-state cooperative vehicle extending reach to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year contract with one-year renewal option; Hall County's RFQ/P #47-010 (posted May 4, 2026, due June 4, 2026) for on-site pharmacy services at the county family health center clinic serving approximately 3,005 eligible plan members, with an initial one-year term beginning January 1, 2027, and four optional renewal periods; and MMCAP's multi-state RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effective July 1, 2026. Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) represents exploratory market intelligence gathering on direct-to-manufacturer prescription models rather than a binding procurement. No set-aside designations appear in the available materials; activity is driven by cost containment, formulary management, and expansion of pharmacy access within government health benefit programs.